Ultomiris (ravulizumab-cwvz) and Soliris (eculizumab), two approved treatments for neuromyelitis optica spectrum disorder (NMOSD), may work better than rituximab — a drug not cleared for treating the autoimmune disease but often used off-label — for preventing NMOSD relapses, according to a new review. Still, the study findings…
relapse prevention
People with neuromyelitis optica spectrum disorder (NMOSD) may experience gradual shrinkage, or atrophy, of the brain even during periods without relapses, according to a new study that challenges the long-held view that most neurological damage in NMOSD occurs mainly during relapses. The researchers also found that starting biologic therapies earlier…
MIL62, an injection therapy approved exclusively in China for neuromyelitis optica spectrum disorder (NMOSD), was found to keep most NMOSD patients free of relapses for up to two years, while being generally safe and well tolerated. That’s according to data from the Phase 1b portion of a single-center…
Use of the approved therapy Uplizna (inebilizumab) reduces the risk of relapse and worsening disability in people with neuromyelitis optica spectrum disorder (NMOSD), regardless of whether patients had previously received conventional immunosuppressive treatments. These are the findings of a post-hoc analysis of data from the Phase 2/3…
Ultomiris (ravulizumab-cwvz) was associated with sustained disease control in people with neuromyelitis optica spectrum disorder (NMOSD), regardless of whether they had been previously treated off-label with rituximab. That’s according to a new analysis of data from the Phase 3 CHAMPION-NMOSD clinical trial (NCT04201262), whose results supported…
For a rare group of neuromyelitis optica spectrum disorder (NMOSD) patients who test negative for two self-reactive antibodies, being older than 32 at disease onset may increase the risk of relapses, a study found. In contrast, spinal cord involvement, with or without optic nerve inflammation, at disease onset was…
For adults with neuromyelitis optica spectrum disorder (NMOSD), rituximab and Uplizna (inebilizumab) work equally well to prevent disease relapses, but Uplizna appears to be safer because it causes fewer infusion-related side effects. Those are the main findings of a real-world study analyzing data from more than 250 NMOSD…
Treatment with Enspryng (satralizumab) for more than two years was shown to prevent relapses in most people with neuromyelitis optica spectrum disorder (NMOSD) in Japan. That’s according to a new study that tracked outcomes from Japanese NMOSD patients given the approved injection therapy in real-world practice. “Overall, most…
Therapies specifically approved by the U.S. Food and Drug Administration (FDA) for neuromyelitis optica spectrum disorder (NMOSD) are superior to rituximab and other off-label medications at preventing relapses and serious side effects, according to a real-world study in the U.S. The study also showed that among FDA-approved therapies, the…
Soliris (eculizumab) is linked to a reduced relapse rate and stabilization of disability progression in people with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-AQP4 antibodies, according to a real-world study in Turkey. “These results support [Soliris] as a valuable therapy for [AQP4-related] NMOSD, while stressing the…